Biomarkers of immune checkpoint inhibitor efficacy in cancer.

Biomarkers of immune checkpoint inhibitor efficacy in cancer. Curr Oncol. 2020 Apr;27(Suppl 2):S106-S114 Authors: Meyers DE, Banerji S Abstract Immune checkpoint inhibitor-based therapies that target ctla-4, PD-1, or the PD-1 ligand PD-L1 have received approval in Canada and many parts of the world for the treatment of melanoma, renal cell cancer, urothelial cancer, classical Hodgkin lymphoma, and non-small-cell lung cancer. However only a small proportion of patients derive long-term clinical benefit. Here, we describe the biomarkers associated with the complex relationship between tumour-related immune stimulus, T cell-mediated immune response, and immune modulation of the microenvironment that can help to predict improved patient outcomes. PMID: 32368180 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research